The never ending success story of tranexamic acid in acquired bleeding

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalReview articlepeer-review


Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis. Although its first clinical use dates back more than 50 years, this hemostatic agent is still the object of intense clinical and developmental research. In particular, renewed interest in TXA has arisen following evidence that it has a beneficial effect in reducing blood loss in a variety of medical and surgical conditions at increased risk of bleeding. Given this characteristic, TXA is currently considered a mainstay of Patient Blood Management programs aimed at reducing patients' exposure to allogeneic blood transfusion. Importantly, recent large randomized controlled trials have consistently documented that the use of TXA confers a survival advantage in a number of globally critical clinical conditions associated with acute bleeding, including traumatic injury and post-partum hemorrhage, without increasing the thromboembolic risk.

Original languageEnglish
Pages (from-to)1201-1205
Number of pages5
Issue number5
Publication statusPublished - May 2020

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The never ending success story of tranexamic acid in acquired bleeding'. Together they form a unique fingerprint.

Cite this